Replimune Group Inc的股价已达到新的52周高点,股价触及12.86美元。这一里程碑反映了这家专注于溶瘤免疫疗法的生物技术公司的显著上升趋势。在过去一年中,Replimune的股票价值增长了13.23%,表明公司业绩强劲,投资者对公司前景的信心不断增强。达到这个52周高点是Replimune财务历程中的一个重要亮点,因为公司继续推进其临床项目并扩大市场份额。
Republicans began scrambling to replace Rep. Elise Stefanik (R-N.Y.) as House GOP conference chair almost immediately after news broke that President-elect Trump had picked her to serve at the United ...
Ltd. t was promoted by Homri R. Patel and his associates. The name was changed to REPL Engineering Pvt. Ltd. on 27th April 1989 and it became a public limited company on 11th July, 1990.
Rudrabhishek Enterprises Ltd (REPL) has received a work order from the Tamil Nadu government to prepare GIS-based master plans for 12 Urban Local Bodies. REPL is into urban development and ...
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to ...
(REPL), a Urban Development & Infrastructure Consultancy, to prepare GIS-based Master Plans for 12 Urban Local Bodies (ULBs) under AMRUT 2.0 Sub-Scheme. The 12 ULBs are under Package 1 and 5.